Read the latest news and research breakthroughs happening at the BC Cancer Agency

“I speak about cancer. I ride my bike. I do these things because I want to change the story. I want a different ending.”
In 2008, Patrick Sullivan lost his young son Finn to an extremely rare form of cancer, rhabdomyosarcoma. A few months later, he was approached by two close friends: “They told me about this fundraising bike ride to Seattle, the Ride to Conquer Cancer. They wanted to put a team in it – and do it in honour of Finn. That was the start of Team Finn.”
Every member of Team Finn is inspired by a little boy who lived every moment of his short life to the fullest. Their distinctive pink jerseys read “Run. Jump. Bounce. Dance. Sing. Love. Smile. Ride,” words that celebrate Finn’s approach to every day.
Finn showed how to live life with courage and joy, and his example has helped Team Finn achieve extraordinary success in raising funds for the BC Cancer Foundation. In just three years, they have raised over $1 million to support cancer research. As Finn’s father says, “Doctors couldn’t change Finn’s story. ‘Incurable’ was his ending. If I could change that for somebody else, then every moment of time is worth it.”

flyout blocks
flyout blocks
Your donations support innovative cancer research and compassionate enhancements to patient care.
flyout blocks
Participate or donate to a fundraising event to support breakthrough cancer research in BC.
flyout blocks
See how your donations are being used to enable the great work at the BC Cancer Agency to continue.
You are here
Gene links rare and unrelated cancers - An important breakthrough in cancer research
Drs. David Huntsman and Gregg Morin link rare, unrelated cancers (ovarian, uterine, and testicular tumours) to a single genetic mutation in DICER1. The discovery shows that the mutations change the function of DICER so that it participates directly in the initiation of cancer. This breakthrough is particularly pivotal because it could lead to solutions for treatment of more common cancers. The discovery is the third in a series of OvCaRe papers to be published in the New England Journal of Medicine.







